Atabecestat (JNJ-54861911) is a potent brain-penetrant and orally active β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor, achieves robust and high CSF Aβ reduction. Atabecestat s tolerated and displays a sustained pharmacokinetic (PK) and pharmacodynamic (PD) characteristics. Atabecestat has the potential for Alzheimer's Disease treatment In Vivo Atabecestat (100 and 300 mg/kg; p.o. once daily for 3 days) reduces the human Aβ levels in mice. Atabecestat (300 mg/kg; p.o. once) inhibits the exacerbation of vascular abnormalities in APPPS1 mice with 3D6 treatment. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: 5-week-old APPPS1 miceDosage: 100 and 300 mg/kg Administration: Oral gavage; 100 and 300 mg/kg; once daily for 3 days Result: Reduced the level of human Aβ 1-40 and Aβ 1-42 levels in the brain of APPPS1 mice at a dose of 300 mg/kg and resulted in less reduction of human Aβ levels at 24 h with a dose of 100 mg/kg. IC50& Target:BACE1
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
Atabecestat
CAS number：1200493-78-2(DMSO) molecular formula：C18H14FN5OS
overview
compound introduction
Specs
| Chinese alias | 阿贝司他 | ||
| English alias | - | ||
| CAS number | 1200493-78-2(DMSO) | molecular formula | C18H14FN5OS |
| molecular weight | 367.40 g/mol | Exact mass | 10mM in DMSO |
| PSA | - | logp | - |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
